Relmada Therapeutics, Inc. vs Cartesian Therapeutics, Inc. — Valuation Comparison 2026
Access all valuation models for RLMD vs RNAC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →RLMD scores higher with a 4.4/10 quality rating vs RNAC's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Relmada Therapeutics, Inc. (RLMD) and Cartesian Therapeutics, Inc. (RNAC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
RLMD currently trades at $7.21 with a QOC of 4.4/10, while RNAC trades at $7.54 with a QOC of 4.4/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).